In today’s episode I’m diving into one of the most important studies we’ve ever seen on GLP-1s — and honestly, one of the most important in metabolic medicine in the last decade. A brand-new analysis just dropped on over 86,000 patients, tracked for up to 10 years, looking at the relationship between GLP-1 agonists and cancer risk. The numbers are staggering. We’re talking 17 percent lower overall cancer risk, 25 percent lower endometrial cancer, 47 percent lower ovarian cancer, and even a 31 percent reduction in brain tumors in people using GLP-1 medications.

This episode is something I’ve wanted to make for a long time. It’s rare that a single study forces you to zoom out and rethink the entire future of chronic disease, but this one does. I walk you through the data, the methodology, why the findings matter, and why this aligns with what I see every day in real-world metabolic optimization work. You’ll hear my perspective on correlation versus causation, how obesity mechanistically drives cancer, and why weight-loss drugs like GLP-1s might play a far bigger role in prevention and longevity than anyone expected.

This isn’t fear-based content. It’s the opposite. It’s hope. It’s the beginning of a shift away from reactionary medicine and toward upstream prevention. Whether you love GLP-1s, hate them, or are just curious, this episode is the clearest look yet at where the evidence is pointing. And as always, I finish with my reflections on why I’m so grateful to get to do this work and share these ideas with you.

If you want to stay connected, get on my email list — that’s where the deep-dive ideas usually hit first before turning into podcasts or videos.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app

Home Top podcasts Popular guests Top books